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1. Introduction 
1.1. Using poly- and oligo-saccharides for drug delivery; Possibility for 
mechanochemical synthesis of supramolecular systems 
Providing efficient ways of delivering active drug molecules to their destinations in target 
organisms, the so-called drug delivery, is among major challenges in today’s pharmacy. An 
important relevant issue is to enhance the efficacy and safety of pharmaceutical compounds 
by correcting their solubility [1-3]. Polysaccharides (e.g., derivatives of cellulose, chitosan, 
and alginic and hyaluronic acids) make part of compositions with controlled or retarded 
drug release [4-6], while oligosaccharides (alpha-, beta-, and gamma-cyclodextrins and their 
derivatives) are broadly used to increase solubility and dissolution rates as they can form 
guest-host supramolecular complexes with poorly soluble drugs [7, 8]. Until recently little 
was known whether complexes of this kind may result from the activity of natural plant-
derived or synthetic water-soluble polysaccharides though these are common elements in 
dietary supplements or drugs. Polysaccharides have aroused no interest in this respect, 
possibly because the technology for producing supramolecular complexes requires liquid 
phases (solutions or melts): The complexes form by molecular interaction in the liquid, and 
the solid phase is extracted then on drying (solutions) or cooling (melts). However, being 
easily soluble in water, polysaccharides are almost insoluble in other solvents and, 
moreover, decompose on heating rather than melt. The target drugs, instead, often dissolve 
rapidly in non-aqueous solvents but are poorly soluble or insoluble in water. Therefore, the 
liquid-phase synthesis of polysaccharide-drug complexes has been impeded by the lack of 
co-solubility.  
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This difficulty may be surmountable with solid-state chemistry approaches, specifically, 
with mechanochemical transformations in mixtures of solids [9-11]. Unlike the liquid-phase 
synthesis, mechanochemical treatment is a simpler single-stage process going without 
solvents or melts and respective additional procedures. The flow chart in Fig. 1 shows a 
simplified sequence of transformations the powder mixtures experience during dry milling 
in various mills.  
There may be three types of main products relevant to our study, depending on the 
properties of starting materials:  
1. “molecular dispersions”, or solid solutions of drugs in excess filling (dispersion 
medium); 
2. supramolecular complexes or products of chemical reactions between the  
components;  
3. composite materials: aggregates of powdered particles. 
In fact, they all are solid dispersions that form supramolecular structures (complexes or 
micelles) that enclose drug molecules and provide their solubility.  
Generally, solid-phase processes have a number of advantages in laboratory and 
technological uses as they yield, in a shorter time, materials which the classical liquid-phase 
technology can never provide and allow avoiding problems associated with melts or 
solvents and side reactions. The high potentiality of mechanical activation was proven in 
our previous studies [12-14], e.g., on quick-dissolving pharmaceutical compositions [15-18] 
and synthesis of polyfluorinated aromatic compounds [19, 20].  
In this synopsis we present techniques for synthesizing supramolecular complexes of poorly 
soluble drugs with water-soluble polysaccharides or with glycyrrhizic acid (a plant-derived 
glycoside), describe physicochemical properties of their solid forms and solutions, and 
report the results of pharmacological testing.  
 
Figure 1. Mechanochemical transformations in mixtures of solids organic substances. 
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2. Physicochemical description of supramolecular systems including 
polysaccharides and glycyrrhizic acid with drug molecules  
2.1. Synthesis of supramolecular systems of water-soluble polysaccharides and 
their stability in aqueous solutions  
In the course of this study, different conditions of mechanochemical synthesis and various 
complexing agents have been tried and compared in terms of efficacy. The complexing 
agents were: arabinogalactan (AG), a water-soluble larch polysaccharide derived from Larix 
sibirica Ledeb. and  Larix gmelinii (Rupr.), fibregum (FG), a glycoprotein of acacia gum, fruit 
pectin (PC), hydroxyethyl starch (HES200/0,5), dextrans (D) 10. 40. 70, and ß-cyclodextrin 
(CD), the latter chosen as standard for being widely used in pharmaceutics. The mixtures of 
powdered components (polysaccharides/complexing agents and drugs) were dispersed in 
ball mills at greater or lower intensities in laboratory planetary- and rotary-type mills, 
respectively. Milder rotary milling was predominantly applied because the molecular-level 
mixing in a planetary mill, common to laboratory studies of mechanochemical modification 
of drugs [9], may partly destroy the material and pose scaling problems. The materials 
processed by nondestructive rotary milling [10, 11, 21], instead, interact to produce solid 
dispersed systems of components (composite aggregates of superdispersed particles), and 
the process is easily scaled onto industrial flow mills.  
The obtained compositions were checked for drug contents to avoid unwanted chemical 
reactions. Formation of supramolecular complexes was identified from changes in solubility 
of drugs in the water solution of the compositions [22].    
Dissolution and complexing of poorly water-soluble drugs can be illustrated by such 
simplified equations: 
 Drugsolid  Drugsolution  (1) 
 Drugsolution + CAsolution  (Drug . CA)solution (2) 
Equilibrium, according to (2), is given by 
 KDCA = [(Drug . CA)solution] / [Drugsolution] x [CAsolution],  (3) 
where Drugsolid is the drug in a crystalline solid phase, in equilibrium with the solution; 
Drugsolution is the drug existing in the free form in the solution; CAsolution is the free 
complexing agent in the solution; (Drug . CA)solution is the complexing agent-drug complex in 
the solution; KDCA is the constant of supramolecular complexing.  
The value Drugsolution corresponds to the thermodynamic equilibrium solubility in the 
absence of complexing agents. In the case of complexing, the total concentration of the 
dissolved drug Cdrug equals the sum its free and bound forms.  
 СDrug = [Drugsolution] + [(Drug  CA)solution] (4) 
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Thus, the solubility increase of a drug in the solution (X) in the presence of a complexing 
agent is  
 X = CDrug /[Drugsolution]  = 1 + KDCA . [CAsolution]  (5) 
In our view, X is a good proxy of binding strength in the supramolecular complexes drugs 
may form with various water-soluble polymers.  
All poorly soluble drugs we studied have shown a notable solubility increase when became 
incorporated into compositions with complexing agents. Table 1 below shows solubility 
data reported in [22-32] as far as published for the first time in this review.  
The binding strength in the complexes grows in the series “dextran 70 < dextrans 40  
and 10 ~ < HES < ß-cyclodextrin, fibregum < pectin < arabinogalactan”. Complexing of 
pectin with mezapam and clozapine most probably occurs by acid-base reactions,  
which accounts for quite a high binding strength. However, other complexing agents  
lack acid-base groups and the interaction mechanism is most likely “hydrophobic”, as in the 
case of cyclodextrin complexes. Thus, the mechanochemical treatment strengthens 
considerably the drug binding in compositions. The solubility of drugs increases, depending 
on the way of mixing, in the series “mixing without milling < high-rate milling < low-rate 
milling. 
The obtained compositions were analyzed by X-ray powder diffraction and thermal 
methods. All non-processed mixtures showed X-ray and thermal features typical  
of crystalline drugs, which disappeared or decreased markedly after milling. Therefore, 
drugs in the ground mixtures partly or fully loose their crystallinity, possibly, as their  
solid phase becomes disordered and their molecules are dispersed into the excess  
solid phase of complexing agents, with formation of solid solutions or supramolecular 
complexes. In the latter case, the solubility changes evidence that the analyzed  
compositions form more strongly bound complexes when form in the solid phase than in 
the solution.  
2.2. Molecular dynamics and structure of arabonigalactan complexes 
AG-drug systems were investigated by 1Н NMR spectroscopy [22] for the molecular 
dynamics of complexes and the mobility of arabinogalactan (AG) molecule fragments.  
NMR relaxometry is applicable to molecular complexes as the spin-lattice and spin-spin 
relaxation times (T1 and T2, respectively) are highly sensitive to interactions and diffusion 
mobility of molecules. As a molecule becomes bound in a complex, its diffusion mobility 
slows down, and the proton relaxation times decrease notably. In the case of rapid complex-
solution molecular exchange, the NMR signal decays according to the mono-exponential 
law. Otherwise, if the exchange is slower than the relaxation time, the kinetics is 
biexponential: 
 1 21 2 22( ) exp( / ) exp( / )A t P t T P t T        (6) 
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API 
Complexing agent/drug 
mass ratios 
 
mass 
Solubility pure 
drug 
[Drugsolution} 
g/l 
/ 
Solubility by 
complexation 
СDrug 
g/l
Solubility 
increase, Х1 Reference 
Diazepam 
Arabinogalactan (1/10)2 0.048/0.058 1.2 [22,24] 
Arabinogalactan (1/10)3 0.048/0.115 2.4 [22,24] 
Arabinogalactan (1/10)4 0.048/2.31 48.2 [23] 
Pectin (1/10)3 0.048/0.67 14.2 [23] 
Hydroxyethylstarch (1/10)4 0.048/0.075 1.53 [23] 
Beta-cyclodextrin (1/10)3 0.048/0.086 1.8 [23] 
Glycyrrhizic acid (1/10)3 0.048/0.16 3.4 [29] 
Dextran 104 0.048/0.09 1.9 [23] 
Dextran 404 0.048/0.092 1.9 [23] 
Dextran 704 0.048/0.057 1.2 [23] 
Indomethacin 
Arabinogalactan (1/10)2 0.04/0.044 1.1 [22,24] 
Arabinogalactan (1/10)3 0.04/0.396 9.9 [22,24] 
Arabinogalactan (1/10)4 0.04/1.59 39.7 [23] 
Hydroxyethylstarch (1/10)4 0.04/0.54 13.5 [23] 
Beta-cyclodextrin (1/10)3 0.04/0.096 2.4 [23] 
Mezapam 
Arabinogalactan (1/10)2 0.02/0.98 4.9 [22,24] 
Arabinogalactan (1/10)3 0.02/0.382 19.1 [22,24] 
Arabinogalactan (1/10)4 0.02/2.81 140.6 [23] 
Pectin (1/10)3 0.02/1.54 77.1 [23] 
Hydroxyethylstarch(1/10)4 0.02/0.04 2.0 [23] 
Clozapine 
Arabinogalactan (1/10)2 0.04/0.176 4.4 [22,24] 
Arabinogalactan (1/10)3 0.04/0.82 20.5 [22,24] 
Arabinogalactan (1/10)4 0.04/4.32 107.9 [23] 
Pectin (1/10)3 0.04/1.63 40.8 [23] 
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Hydroxyethylstarch(1/10)4 0.04/0.222 5.5 [23] 
Beta-cyclodextrin (1/10)3 0.04/0.60 15.1 [23] 
Glycyrrhizic acid (1/10)3 0.04/0.088 2.2 [29] 
Nifedipine 
Arabinogalactan (1/10)3 0.18/1.24 6.9 [26] 
Arabinogalactan (1/20)3 0.18/2.46 13.7 [26] 
Glycyrrhizic acid (1/10)3 0.18/0.92 5.1 [30] 
Dihydro-
quercitin 
Arabinogalactan (1/10)4 0.65/3.75 5.9 [23,27] 
Hydroxyethylstarch(1/10)4 0.65/1.97 3.0 [23] 
Fibregum(1/10)4 0.65/5.72 8.8 [23,27] 
Quercitin 
Arabinogalactan (1/10)3 0.019/0.21 11.6 [28] 
Arabinogalactan (1/20)3 0.019/1.28 71.0 [28] 
Ibuprofen 
Arabinogalactan (1/10)2 0.03/0.036 1.2 [29] 
Arabinogalactan (1/10)4 0.03/0.85 28.4 [29] 
Hydroxyethylstarch (1/10)4 0.03/0.08 2.6 [29] 
Glycyrrhizic acid (1/10)3 0.03/0.441 14.7 [29] 
Beta-Carotene Arabinogalactan (1/40)3 < 0.001/2.65 > 2000 
[25], This 
article 
Warfarin Arabinogalactan (1/40)3 0.021/0.111 5.3 [31] 
Contaxantine Arabinogalactan (1/40)3 < 0.001/2.64 > 2000 
[25], This 
article 
Albendazol 
Arabinogalactan (1/10)4 0.003/0.174 58.0 [32] 
Hydroxyethylstarch(1/10)4 0.003/0.094 31.3 [32] 
Carbenazim 
Arabinogalactan (1/10)4 0.009/0.146 16.2 [32] 
Hydroxyethylstarch(1/10)4 0.009/0.020 2.1 [32] 
Simvastatin 
Glycyrrhizic acid (1/10)3 0.0012/0.314 260 This article 
Arabinogalactan (1/10)3 0.0012/0.044 36,7 This article 
1 – To determine the solubility of the drug, machined mixture of complexing agent/drug, in amounts of 0.4 grams, as 
well as the linkage of individual substances which are equivalent to their content in the above mixture was dissolved 
in 5 ml of water while stirring with a magnetic stirrer at +25 ° C till reaching constant concentration.  The concentration 
of drug in the solution was analyzed by HPLC. 
2 – mixing without mechanical treatment; 
3 – treatment in a planetary mill, acceleration 40 g; 
4 – treatment in a rotary ball mill, acceleration 1 g; 
Table 1. Increase in water solubility of some drugs as a result of complexing. 
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The fast component P1 and the slow component P2 correspond, respectively, to the shares of 
molecules in the complex and in the solution. Typical T2 values are 0.5-1 s for molecules in 
the solution and 0.03-0.09 s for those bound in the complex. Shorter T21 times mean lower 
mobility of drug molecules in the latter case. 
Similar considerations apply to the mobility within polymers when parts of a 
macromolecule differ in mobility, possibly, controlled by their spin and conformations.  
2.2.1. T2 measurements 
Arabinogalactan shows biexponential relaxation patterns. The calculated parameters for 
arabinogalactan and AG-drug complexes are listed in Table 2.  
 
Sample 
P1 
% 
T21 
msec 
P2 
% 
T22 
msec 
Arabinogalactan, native2 80 17 22 250 
Arabinogalactan, treated in planetary mill2 65 25 35 250 
Clozapine/Arabinogalactan 1/20 w/w  
No treatment3 
88 90 12 1000 
Clozapine/Arabinogalactan  1/20 w/w 
Mixture treated in planetary mill3 
90 40 10 1000 
Mezapam/Arabinogalactan 1/20 w/w 
No treatment3 
55 50 45 250 
Mezapam/Arabinogalactan 1/20 w/w 
Mixture treated in planetary mill3 
90 30 10 250 
Diazepam/Arabinogalactan 1/20 w/w 
No treatment3 
mono 150 - - 
Diazepam/Arabinogalactan 1/20 w/w 
Mixture treated in planetary mill3 
20 60 80 800 
Indomethacin/Arabinogalactan 1/20 w/w 
No treatment3 
58 50 42 900 
Indomethacin/Arabinogalactan 1/20 w/w 
Mixture treated in planetary mill3 
67 40 33 900 
1 - T2 measurements were performed for the aromatic protons of drug molecules, to an accuracy of ± 10% 
2 – solvent D2O; 
3 - solvent  70% D2O + 30% CD3OD; 
Table 2. Spin-spin relaxation times of protons for arabinogalactan and drug molecules in solutions1  
The short relaxation times may correspond to the interior protons and the long times may 
represent the exterior protons of the polymer compound. Mechanical activation in a 
planetary mill increases the molecular mobility of the interior fragments but decreases their 
percentage. A relatively narrow ~ 6 kHz band in the 1H NMR spectra of AG powder, which 
stands out against a broad line associated with dipole-dipole interaction non-averagable in 
solids, represents a mobile phase with its integral intensity up to ~ 15% of the number of 
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hydrogen nuclei in the sample. The mobile phase may correspond to fragments of AG 
macromolecules, possibly, side chains, as one may reasonably hypothesize given that water 
content in AG never exceeds 2 wt.%. This very fact appears to facilitate AG-Drug molecular 
complexing on mechanical activation of solids.  
AG-Drug systems most often exhibit distinct biexponential kinetics as evidence that the drug 
molecules are either free or bound in complexes with AG. The bound molecules are more 
abundant and less mobile in milled samples, while the free ones keep almost invariable 
NMR relaxation times. The characteristic 1H NMR bands of clozapine and mezapam move 
to low field on complexing, possibly because the molecules become protonated at the 
account of minor remnant uronic acid present in AG, the shift being likewise greater in the 
milled samples. However, no complexing-related shifting appears in the cases of 
indomethacin and diazepam. The life time of drug molecules in complexes with AG must to 
be ~> 100 ms, judging from the conditions of slow exchange. 
The system AG-diazepam offers an illustrative example. Solutions of these mixtures not 
subjected to mechanical treatment show mono-exponential relaxation behavior, but with 
shorter times than in free diazepam, likely as a result of rapid solution-complex molecular 
exchange. The milled mixtures, on the contrary, have biexponential kinetics corresponding 
to slower exchange of molecules and stronger binding.  
Thus, dynamic NMR spectroscopy of all Drug-AG solutions indicates formation of 
supramolecular drug-polysaccharide complexes, like the data on solubility increase. Most 
likely, the complexing sites are at side chain spaces in the branching macromolecules. Unlike 
cyclodextrins, ensembles of polysaccharide molecules (including arabainogalactan) are 
micro-heterogeneous in mass and structure. As a result, molecular modeling of the complex 
is very difficult. The binding mechanism appears to lie mainly with hydrophobic 
interactions [33, 34] which are typical of guest-host cyclodextrin complexes. A certain 
support to this hypothesis comes from stronger binding of highly lipophilic drugs which are 
almost insoluble in water. In this case, the branched structure of AG macromolecules [35, 36] 
is especially favorable for complexing. However, Coulomb interactions may contribute as 
well in the presence of acid-base groups in polysaccharides and drugs [37].  
2.3. Transformations of polysaccharides in solid state and in solutions  
Macromolecules characteristically have broadly varying molecular weights, from ~103  
to ~107 Da. Macromolecules in polymers involved in technological production of various 
materials may experience mechanical action and partial destruction (breakdown of chains) 
whereby their molecular weight becomes ever more heterogeneous and diminishes on 
average [38]. The destructive change may be especially prominent in “dry” technological 
processes, such as pulverization, pelleting, or mixing, e.g., in mechanochemical solid-state 
complexing of drugs with water-soluble polymers (polysaccharides). Partial destruction of 
polymers may change their toxicological properties which have to be cautiously monitored 
when making new drugs and food products.  
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Molecular weight patterns were studied [39] in polysaccharides (dextrans 10, 40, and 70, 
HES 200/0.5, and larch AG and acacia FG gum) by gel permeation chromatography (GPC) 
[40] of samples treated in rotary and planetary mills; the obtained materials were tested for 
their toxicity.   
See Fig. 2 for example chromatograms of AG and Table 3 for calculated molecular weights 
of the analyzed polysaccharides before and after mechanical treatment. 
 
Figure 2. GPC chromatograms of 0.02 wt.% arabinogalactan water solution. 1 = native; 2 – 5 = subjected 
to mechanical treatment: ball mill, 2 hours (2), ball mill, 24 hours (3), planetary mill, 10 min (4), 
extremely intense treatment, mixed ball loading (5); Eluent: H2O/0.1 N LiNO3 
Polysaccharides ground in a high-rate planetary mill diminish markedly in molecular 
weight and change slightly their polydispersity index Mw/Mn. The mechanical destruction 
is stronger in polymers with larger molecular weights, which agrees with published 
evidence [39]. Note that highly branching macromolecules (HES and AG) break down into 
roughly equal fragments. The Mw/Mn ratios in polysaccharides do not grow much, 
possibly, because destruction mostly affects their high-molecular fractions. Destruction is 
apparently controlled by the structure of polysaccharide molecules and physicochemical 
chain breakdown mechanisms. According to a model for linear synthetic polymers [41], the 
chains that occur in the middle of macromolecules are especially prone to failure. 
Destruction of HES and AG is qualitatively similar to that model, though dextrans and 
fibregum may deform by a different mechanism.  
The results for larch arabinogalactan are worth of special consideration. High-rate treatment 
in a planetary mill, especially with mixed ball loading reduces strongly the AG molecular 
weight. According to chromatograms (Fig. 2), its Mw 17.3 kDa macromolecules split 
quantitatively into two almost equal parts of Mw = 8.3 kDa, while their Mw/Mn ratio 
decreases to 1.08 [23]. Therefore, the native AG molecules may consist of two relatively 
weakly bonded fragments of equal molecular weights and easily break down on milling 
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[23,39]. Note that AG macromolecules with MM (Molecular Mass) ~9 kDa are likewise the 
main product of chemical destruction of Canadian larch AG [42]. 
Furthermore, the analyzed polysaccharides experience almost no mechanical failure on low-
rate grinding in a rotary mill (Table 3). Thus, ball rotary milling appears to be most often 
preferable, as molecular mass changes in technologically produced polymers are commonly 
unwanted in view of their further use in dietary supplements and drugs, otherwise 
additional tests and standardization may be required.  
 
Sample Treatment 
Mn, 
kDa 
Mw, 
kDa 
Mw/ 
Mn 
Weight shares of 
macromolecules, 
kDa 
10% 90% 
Fibregum 
Native 146.6 256.7 1.8 <75.9 <528.2 
Planetary mill, 20g, 20min 31.4 55.2 1.8 <16.3 <113.5 
Ball mill, 1g, 4hours 120.3 231.6 1.9 <60.3 <478.4 
Arabinogalacta
n 
Native 13.9 17.3 1.2 <9.0 <27.9 
Planetary mill, 20g, 20min 9.3 11.2 1.2 <6.1 <18.4 
Ball mill, 1g, 4hours 13.1 16.3 1.2 <8.1 <26.2 
Hydroxyethyl 
starch 200/0,5 
Native 47.9 116.9 2.4 <20.9 <265.3 
Planetary mill, 20g, 20min 26.6 55.2 2.1 <12.7 <118.9 
Ball mill, 1g, 4hours 45.6 105.5 2.3 <20.0 <237.6 
Dextran 70 
Native 30.9 76.4 2.5 <14.0 <174.7 
Planetary mill, 20g, 20min 22.7 54.8 2.4 <10.4 <123.5 
Ball mill, 1g, 4hours 29.6 73.5 2.5 <13.4 <169.2 
Dextran 40 
Native 24.6 38.0 1.5 <13.3 <72.3 
Planetary mill, 20g, 20min 19.5 31.9 1.6 <10.4 <61.3 
Ball mill, 1g, 4hours 24.3 37.4 1.5 <13.0 <71.2 
Dextran 10 
Native 8.3 13.4 1.6 <4.2 <26.4 
Planetary mill, 20g, 20min 8.0 12.1 1.5 <41.9 <22.7 
Ball mill, 1g, 4hours 8.3 13.4 1.6 <4.2 <26.3 
Table 3. Molecular mass distribution of polysaccharides 
Toxicological tests of the milled polysaccharides show that a single intragastric injection 
administered at doses from 500 to 6000 mg/kg body weight caused no death in experimental 
animals. Their appearance, behavior, and state were within the background over the whole 
dose range; no statistically significant changes in body temperature relative to the control 
was observed, and body weight growth was uniform in all groups. Injections of the tested 
polysaccharides neither induced any considerable effect on the central nervous system of 
the mice. Patomorphological postmortem examination of mice in 14 days after 
polysaccharide administration revealed no pathology in thoracic and abdominal cavities. 
The median lethal dose LD50 for all polysaccharides was over 6000 mg/kg body weight on 
single intragastric injection.  
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2.4. Supramolecular structures of glycyrrhizic acid (GA) and poorly 
soluble drugs water solutions: Synthesis and properties  
Biosynthetic and natural plant-derived carbohydrate-bearing metabolic agents have  
been increasingly used for obtaining complexes (clathrates) with drugs in drug delivery 
research. The mechanism of GA-pharmacon interaction in solutions may consist in 
involving drug molecules into self-associates (micelles) that exist in a wide range of 
concentrations in GA solutions. Until recently however, the existence of micelles in GA 
solutions had no direct proof but was either inferred from measured concentration 
dependences of solution viscosity [43] or was studied by dynamic NMR spectroscopy in 
water-methanol solutions [44]; the latter (30% concentration) were at the same time used as 
solvent for technical reasons. Thus, the molecular mechanism of drug complexing remained 
unclear, whether it was incorporation into micelles or supramolecular complexes with GA 
in water solutions, without organic solvents which change notably the GA-pharmacon 
reactions.    
GA water solutions, with and without the presence of poorly soluble drugs, were 
investigated in [29] using gel permeation chromatography, which allows detecting self-
associates/micelles and estimating their sizes and concentrations. On the other hand, solid 
GA-drug dispersions were obtained with the mechanochemical approach developed earlier 
[10, 11]. The binding strengths in GA-pharmacon supramolecular complexes or GA micelles 
in water solutions were compared using the criterion of solubility increase in poorly soluble 
drugs [22] and studied in terms of pharmacological activity.  
Chromatograms of GA water solutions (Fig. 3) show peaks of high-molecular (~ 46-67 kDa) 
forms over all studied concentration ranges, while the GA molecular weight is 836.96 Da 
(Table 4).  
The peak areas, being proportional to the solution concentrations and calculated relative to 
the known amounts of standard dextrans, show that almost all GA is stored in the solution. 
This, in our view, is evidence for the existence of GA self-associates (micelles). The  
critical concentration of micelle formation (CMC) was estimated earlier [43] from viscosity 
change in GA solutions to be 0.004 wt. % (0.05 mM). In our case estimating exact CMC is 
difficult for the limited sensitivity of refractometric detector and for dilution in the 
chromatographic column. However, it may be inferred from the time to the 
chromatographic peak (~0,5 min) and the elution rate. The solution we studied underwent 
about 10-fold dilution, and the derived CMC is ~< 0.0001 wt.%, (0.001mM), or far less than in 
water-methanol solution (0.04-0.08 wt.%  or 0.5-1.0 mM) [44]. In diluted 0.01-0.001 wt. % 
solutions, there is only one type of micelles (~ 66 kDa) with a very low Mw/Mn ratio of  
1.08-1.06. As the GA solutions reach concentrations of 0.5 wt.%, micelles decrease in weight 
to form ~ 46 kDa bodies and increase in Mw/Mn ratios. Therefore, almost all glycyrrhizic 
acid in water solutions from 0.0001 to 0.5 wt.% exists in the self-associated form of micelles, 
out of which the ones with MM= ~ 66 kDa consisting of about 80 GA molecules are most 
stable.  
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Figure 3. GPS chromatograms of glycyrrhizic acid water solution. 1 - concentration - 0.001, 2 - 0.01, 3 - 
0.1, 4 - 0.5 wt.%. 
 
COMPOSITION 
Molecular 
masses 
Solution concentration, wt. % 
0.001 0.01 0.1 0.5 
GLYCYRRIZIC ACID 
Mw/Mn 
kDa 
65.93/61.0 66.2/62.5 60.7/57.3 45.3/36.5 
GLYCYRRIZIC ACID/ 
/IBUPROFEN 
10/1 w/w 
Treated in planetary 
mill 3 min 
Mw/Mn 
kDa 
69.0/67.2 69.4/65.3 65.2/61.7 48.6/39.0 
Table 4. Molecular-mass characteristics of micelles in solutions of glycyrrhizic acid and its composition 
with ibuprofen 
2.4.1. GA solid dispersions with poorly water-soluble drugs 
Solid GA dispersions with ibuprofen, phenylbutazone, clozapine, and diazepam were 
obtained by milling with GA (10:1 mass, or 2.5/1 – 4/1 molar ratios). Their thermal analysis 
data indicate that the crystalline phase of the drugs becomes disordered, until complete loss 
of crystallinity. In our view, the molecules of drugs may disperse into the excess solid GA 
with formation of solid solutions. Other investigated systems behave in a similar way.   
As the dispersions dissolve, the drugs become more soluble in water (Table 1), this being 
evidence of the efficiency of GA as a solubilizing agent and the mechanochemical treatment 
as a tool for synthesis of water-soluble solid dispersions. GA has a nearly intermediate 
solubilizing effect higher than HES but lower than AG.  
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2.4.2. GPC of dissolved GA-drug solid dispersions  
The GPC data for GA-ibuprofen dispersions in water are shown in Table 4.  Similar results 
of MM increase in micelles were obtained for the GA-diazepam, GA- phenylbutazone, and 
GA-clozapine systems. The peak areas, proportional to the concentrations of the analyzed 
solutions, indicate that they bear almost the entire mass of GA-drug samples. Thus, the 
dissolved drugs in the GA-drug complexes are likewise self-associated in micelles which are 
stable in a broad range of concentrations, as well as in the solutions of native GA. Therefore, 
we suggest that poorly soluble drugs increase their solubility by incorporating into GA 
micelles/self-associates. GA molecules contain a hydrophilic (two glucuronide residues) and 
a hydrophobic (triterpene) components (Fig. 4).  
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Figure 4. The structure of glycyrrhizic acid 
In micelles, the latter are most likely oriented inward and the former toward the outer surface 
of the self-associate, while the drug molecules may occur either in the interior hydrophobic 
part or complex with the exterior hydrophilic part of the micelles. Unfortunately, the 
experimental evidence is insufficient to judge about these subtle GA-drug interaction 
mechanisms. Generally, the MM of GA-pharmacon micelles are 5-7% higher than those in GA 
water solutions, all over the studied range of concentrations. Another possibility is that drug 
molecules may substitute for some GA molecules while the micelles generally grow in size.  
As the solution concentration increases, the size difference of micelles grows correspondingly. 
Note that the region of high GA concentrations is proximal to the conditions in which  
the solubility of drugs was measured, this being additional evidence for the suggested 
mechanism of water solubility increase. An explanation for the decreasing MM differences on 
dilution may be that drug molecules can escape from GA micelles during GPC process to 
diluted solutions and appear in chromatograms as individual substances eluted at different 
rates [45]. Anyway, further investigation is needed to gain more insights into the GA-drug 
interaction. 
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3. Pharmacological activity of supramolecular complexes 
The pharamacological activity of the complexes was investigated in vivo on females and 
males of outbred white mice and on Wistar rats, obtained from the SPF vivarium of the 
Institute of Cytology and Genetics, Novosibirsk. All animal procedures and experiments 
followed the 1986 Convention on Humane Care and Use of Laboratory Animals. The 
activity was determined using standard pharmacological tests [46]. All studied complexes, 
with some exceptions, are AG-Drug or GA-Drug compositions of 10:1 weight ratio, which 
was found out to be of greatest efficacy [22].  
3.1. Arabinogalactan-drug complexes 
As a special study has shown, AG complexing with nonsteroidal anti-inflammatory drugs 
and non-narcotic analgesics of various action mechanisms can reduce the required dose for 
5-100 times and, hence, avoid the side effects typical of the drugs.   
For instance, complexing with indomethacin allows 10 to 20 times dose reduction relative to 
the standard and induces twice fewer cases of lesion to gastric mucous membrane, with the 
same high anti-inflammatory activity [22, 24]. 
Administration of phenylbutazone in a complex with AG, at ten times lower pharmacon 
content, stimulated analgesic activity, both in the model of chemical effect and on thermal 
action, which may expand its applicability scope (Table 5). 
 
Compounds Hot plate, s 
Acetic acid writhing model, 
amount 
Control 28.73±2.34 4.76±0.26 
Phenylbutazone:AG 1:10. 120 mg/kg per os 42.20±5.20* 2.00±0.09* 
Phenylbutazone, 12 mg/kg per os 11.40±0.80 4.25±0.50 
Ibuprofen:AG 1:10. 200 mg/kg per os 23.50±2.43 0.75±0.01* 
Ibuprofen, 200 mg/kg per os 19.5±2.45 1.50±0.03* 
Metamizole sodium: 
AG 1:10. 50 mg/kg per os 
32.50±3.70 1.75±0.08 
Metamizole sodium, 50 mg/kg per os 30.40±3.20 0.63±0.10 
Metamizole sodium, 5 mg/kg per os 17.70±2.30 4.25±0.75 
*p <0.05 relative to control 
Table 5. Analgesic activity of AG complexes with non-narcotic analgesics 
AG complexes with 10 times smaller doses of ibuprofen and metamizole sodium showed  
a high analgesic activity in visceral pain models (the former) and in two models of  
test pain.  
Studies in this line were continued, with the above approach and proceeding from the 
obtained results, on AG complexes with drugs that involve the central nervous system. 
Specifically, AG complexing with diazepam allowed reducing the dose for ten times and 
enhanced the anxiolytic effect. AG complexes with mezapam acted as standard anxiolytics 
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at 20 times lower doses of the phamacon. The AG-clozapine complexing provides a two-fold 
dose decrease at a higher sedative action.  
Another objective was to study drugs involving the blood coagulation and cardiovascular 
systems. The AG-warfarin (WF) complex was tested on intragastric injection in females of 
Wistar rats, with prothrombin time (PT, in seconds) as the principal criterion of the action. 
PT is the classical laboratory test of the exterior blood coagulation pathway used to evaluate 
the system of hemostasis in general and the efficacy of warfarin therapy in particular. The 
complex was administered once, in a dose of 20 mg/kg body weight, which is equivalent to 
2 mg/kg warfarin. In 24 hours after the injection, PT increased considerably (to 30 s against 
the 11.63 s for the intact control). With free warfarin, this time was 42 s, or 28.5% longer than 
with the AG-warfarin complex, but it equalized (21 s) for both agents in 48 hours after a 
single injection (Fig. 5,6). 
 
Figure 5. Prothrombin time, 24 hours after  single dosing of WF:AG and WF:GA. 
 
Figure 6. Prothrombin time, 48 hours after single dosing of WF:AG and WF. 
The difference in pharmacokinetics between the AG:WF complex and free warfarin was 
further explored after a single administration of 20 and 2 mg/kg body weight, respectively. 
Blood was sampled in 1, 8, 10, 12, 24, 48, and 72 hours after injection on decapitation. Fig. 7 
shows average plasma warfarin contents, and pharmacokinetic parameters are listed in 
Table 6. The concentrations of the compounds increase in a similar way but free warfarin 
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30,03
42
49,4
11,63
0 10 20 30 40 50 60
WF:GA, 20 mg/kg
WF:AG, 20 mg/kg
WF, 2 mg/kg
WF Nyc, 2 mg/kg
Saline
A
g
e
n
ts
Prothrombin time, sec.
21,21
21,73
0 5 10 15 20 25 30
WF, 2 mg/kg
WF:AG, 20 mg/kg
A
g
e
n
ts
Prothrombin time, sec
 
The Complex World of Polysaccharides 588 
reaches Cmax seven hours sooner (Tmax) than in complexes with AG, and the concentrations 
become equal in 24 hours after single dosing. Excretion, on the contrary, is slower in pure 
warfarin than in the complex, which is consistent with 27 % higher clearance (CL) in the 
complex than in the free drug. Thus, warfarin increases more smoothly when bound with 
AG than in the free form and thus poses lower bleeding risks associated with its abrupt rise 
during dosage adjustment. Furthermore, shorter mean retention times (MRT) for the AG:WF 
complex may secure the following injection and accelerate warfarin excretion in the case of 
drug withdrawal. 
Thus, complexing of warfarin with AG increases its safety and reduces unwanted bleeding 
risks in the case of anti-coagulant treatment.   
 
Figure 7. Mean plasma concentration–time profile of WF:AG and blank WF after single oral 
administration at a dose of 20 mg/kg (dose of WF is equal to 2 mg/kg) and 2 mg/kg, respectively. 
 
Compounds WF, 2 mg/kg WF:AG, 20 mg/kg 
CL, ml/h 1.52±0.03 1.93±0.18* 
MRT, h 31.39±1.82 21.81±2.38* 
Terminal half life, T1/2, h 5.11±0.24 6.38±2.55 
Tmax, h 11.00±1.41 18.00±8.49 
Cmax, μg/ml 6.47±0.91 5.64±0.19 
AUC, μg h/ml 263.01±0.02 208.34±20.03* 
*p<0.05 against WF 
Table 6. Pharmacokinetic parameters of WF and WF:AG 
Another drug in which we studied the pharmacological effect of complexing with AG was 
nifedipine (NF). NF is a dihydropyridine blocker of slow calcium channels that dilates 
coronary and peripheral vessels and reduces the oxygen demand in myocardium. 
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Nifedipine exerts a minor negative inotropic effect and a very weak antiarrhythmic action. 
Intravenous injection of 3.5 mg/kg AG:NF complex (0.35 mg/kg NF) caused 26 % drop of 
blood pressure, measured via a carotid cannula, while 0.35 mg/kg NF can provide only a 9% 
decrease.  
Being aware that nifedipine has a pleiotropic antiarrhythmic effect, besides the basic 
hypotensive action, the NF:AG complex was investigated in this respect on intravenous 
injection in a model of arrhythmia induced with 250 mg/kg calcium chloride. The complex 
administered in a dose of 0.175 mg/kg body weight (0.0175 mg/kg NF) arrested lethal heart 
rate disorder in 100% and 65% of cases, respectively, when applied prior to and after 
exposure to the arrhythmogen. Pure NF at 0.0175 mg/kg had no antiarrhythmic effect in the 
model of calcium chloride arrhythmia.  
Thus, the NF:AG complex has demonstrated a stronger hypotensive and antiarrhythmic 
action than pure NF on intravenous administration, while its effective hypotensive dose is 
ten times smaller. Arabinogalactan itself does not induce any statistically significant 
decrease in blood pressure and cardiac rates. Furthermore, it is important that the new 
method adds another water-soluble form of NF as there is the only soluble nifedipine 
(adalate) available in the market.  
A similar hypotensive effect was obtained with nisoldipine, another dihydropyridine.  
Complexing of hypoglycemic drugs (metformin, rosiglitazone, insulin) with AG increased 
their solubility but allowed no dose reduction, though it improved notably the state of 
animals exposed to a toxic dose of alloxan, an agent simulating trial hypergclycemia.  
The reported pharmacological data on the AG complexes with these pharmacons agree with 
the results on complexing with terpenoids (glycirrhizic acid, stevioside, and rebaudioside). 
In both cases, complexing increases the basic activity of drugs, allows dose reduction and 
forms new properties. We suggest to call this effect complexing or clathration of 
pharmacons with plant-derived carbohydrate-bearing metabolic agents.  
3.2. Glycyrrhizic acid (GA)-drug complexes  
3.2.1. Nonsteroidal anti-inflammatory drugs (NSAID)  
GA:NSAID complexes with acetylsalicylic acid (ASA), diclofenac (OF), phenylbutazone 
(BD), and indomethacin (IM) were synthesized in solutions [24] and in solid state [23]. 
Complexing was confirmed by spectrometry. In IR spectra, the bands of hydroxyl and 
carbonyl groups of the glycoside were shifted to short wave numbers. 
All mentioned complexes show anti-inflammatory action in smaller doses than the primary 
drug, and have 3-11 times larger therapeutic index (LD50 /ED50) [47,48] (Table 7). 
GA complexes with aspirin and diclofenac (GA:ASA, GA:OF) exerted a prominent  
anti-inflammatory action in six models of acute inflammation induced by carrageenan, 
formalin, histamine, serotonin, Difko’s agar, and trypsin, as well as in the cases of  
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chronic inflammation (cotton and pocket granulomas) in intact and adrenalectomized 
animals [48]. 
 
Compounds Dose range of complex* Dose range of free NSAID 
GA : ASA (1:1) 
GA: OF (1:1) 
GA : BD (1:1) 
GA : AN (1:1) 
4500/82=54.8 
1750/12.5=140 
3150/62=50.8 
8000/68=117.6 
1900/98=19.4 
310/8=33.7 
880/56=15.7 
570/55=10.3 
Table 7. Anti-inflammatory effects of GA complexes and free NSAID.LD50 /ED50; ED50 – effective dose 
The anti-inflammatory action of the GA:IM complex is stronger than of the free drug at 
equal dosing (10 mg/kg body weight). GA:NSAID complexing also potentiates other 
(analgesic, antipyretic) biological activities [29]. The GA:OF complex exerted a more 
prominent anesthetic action than diclofenac in electric and thermal stimulation (57.5±2.0 
and 43.2±2.6) and exceeded the amidopyrine effect in the case of thermoalgesic 
stimulation (23.4±1.1 and 18.5±1.4). The anesthetic activity of the GA: metamisole  
sodium (GA:AN) complex is 11.4 times higher relative to metamisole sodium (AN) alone 
[23] while and that of the GA:ASA complex exceeds the effect of aspirin in animals 
exposed to thermoalgesic stimuli. The GA complexes with ASA and OF are 3 and  
2.3 times more potent pain relievers than the respective NSAID in acetyl choline  
writhing model. The GA:ASA complex demonstrates a 4 times higher therapeutic  
index than aspirin in the acetic acid writhing model. The GA:ASA and GA:ОF  
complexes show high antipyretic activity, twice larger than in the pure pharmacons 
[47,48]. 
Thus, water-soluble GA:ASA and GA:ОF complexes evoke prominent anti-inflammatory 
and antipyretic effects, their spectrum of pharmacological activities and therapeutic ratio 
being larger than in the respective NSAID. The complexes also induce a marked membrane-
stabilizing effect and reduce accumulation of primary and secondary products of lipid 
peroxidation in animals with chronic inflammation.   
Complexing of glycyrrhizic acid with ibuprofen increases the analgesic action of the latter at 
twice lower doses.  
Furthermore, GA complexes irritate less strongly the gastric mucosal membrane than  
their NSAID counterparts. For instance, the GA:ASA complex promotes reparation of  
ulcers though the ulcerogenic activity of GA:ОF is minor. Both complexes diminish Е1  
and Е2 blood prostaglandins in animals with chronic inflammation. The complexes  
can be recommended for clinical trials as anti-inflammatory agents, including for  
patients that suffer from ulcer of stomach and duodenum. The acute toxic effect of 
GA:NSAID complexes is 2 to 14 times as low as in the respective pharmacons (Table 8)  
[47, 48]. 
GA:NSAID complexing obviously exerts a synergetic effect of higher biological activity 
along with lower toxicity and weaker ulcerogenic action on the gastrointestinal tract, and 
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has a higher water solubility. It is evident on comparing the pharmacological activities of the 
ASA:GA and OF:GA supramolecular complexes obtained by dissolution and solid-state 
mehcanochemical synthesis that the latter opens a promising perspective of a 
technologically preferable and saving way of producing highly active NSAI drugs [23]. 
 
Complexes LD50, mg/kg Pharmacon LD50, mg/kg 
GA : ASA (1:1) 
GA: OF (1:1) 
GA : BD (1:1) 
GA : AN (1:1) 
4500 
1750 
3150 
8000 
1900 
310 
880 
570 
Table 8. Acute toxicity of GA:NSAID complexes in mice (per os) 
The GA:Rofecoxib complex at doses 50 and 100 mg/kg body weight shows no active anti-
inflammatory and analgesic effects but is more highly soluble.  
3.2.2. Prostaglandins  
Prostaglandins have been of broad use in human and veterinary medicine for their ability, 
in small doses, of stimulating womb muscles.  
Veterinary uses of prostaglandins have been especially important: prostaglandin-based 
drugs are employed in swine breeding for farrow synchronization and are highly potent in 
preparing cattle and horse females for artificial insemination; these drugs allowed solving 
many problems with puerperal complications in cows and horses.  
Kloprostenol, one main veterinary drug, is made by multistage synthesis, like other 
prostaglandins, which imposes its high price. It is urgent to reduce the effective dose and at 
the same time to increase the stability of labile prostaglandins in finished drugs. Both 
solutions have been found through complexing E and F prostaglandins (PGE1, PGE2, 
PGF2α), sulprostone (SP) and kloprostenol with GA. The complexes were synthesized and 
tested for uterotonic activity (Table 9).   
In experiments on rats and guinea pigs, the GA:PGE1 (1:1) and GA:PGF2α (1:1) complexes 
changed the amplitude of uterine actions twice more strongly than the same concentration 
of PGE1 sodium (10-8 g/ml). SP and PGE2 as complexes with GA (1:1) induced three times 
greater amplitudes and increased uteric tonicity [49]. 
An efficient veterinary drug of klatraprostin has been developed on the basis of GA 
complexing with kloprostenol, a well known synthetic luteolitic prostaglandin, at doses five 
times as low as in the world practice [48, 49]. The drug is cheaper than its imported analogs 
while its action is more physiological than in the best foreign counterparts.  
Klatiram, which contains an aminoacid (tyrosine) besides GA and kloprostenol [48,49], has a 
still greater potency. It is more effective than estrofan though bears 100 times less 
prostaglandin (kloprostenol).  
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Compound 
Change of uterine 
contraction amplitude, % 
P 
Change in uterus 
tonus, % 
Р 
GA: PGE1 53.4±5.0 <0.002 49.4±1.2 <0.002 
PGE1 24.3±1.5 <0.05 30.7±2.2 <0.05 
GA : SP 150.0±11.0 <0.001 135.0±10.0 <.001 
SP 50.0±5.0 <0.001 115.0±9.5 <0.001 
GA : PGE2 63.5±6.0 <0.001 40.7±4.0 <0.002 
PGE2 20.0±2.8 <0.05 33.5±2.4 <0.05 
GA: PGF2α 55.6±5.0 <0.001 61.0±5.6 <0.001 
PGF2α 27.8±1.5 <0.05 39.4±5.3 <0.02 
Table 9. Uterotonic activity of prostaglandins and their GA complexes (1:1) in rats ex vivo, phosphate 
buffer C = 10-8 g/ml. PGE1 , PGE2, SP, PGF2α. 
3.2.3. Cardiovascular drugs and anticoagulant warfarin  
Pharmacological activity was also investigated in GA complexes with antiarrhythmic 
Lappaconitine hydrobromide (LA) and antihypertensive nifedipine (NF) drugs. 
Lappaconitine hydrobromide belongs to the group of clinically used antiarrhythmic drugs 
and is administered to patients with various rhythm disorders, especially, ventricular 
arrhythmia, paroxysmal ciliary arrhythmia, and monofocal atrial tachycardia, but it has a 
drawback of high toxicity.  
In special experiments on antiarrhythmic action of LA:GA complexes, the one patented as 
alaglizin [50] showed the highest efficacy. Alaglizin, being ten times less toxic than LA, 
induced antiarrhythmic effects in models of calcium chloride and aconitine arrhythmia and 
had the highest antiarrhythmic therapeutic index (LD50/ED50) among all available drugs of 
this kind. When administered at 0.125 mg/kg and 0.250 mg/kg body weight, alaglizin 
causes no influence on electrocardiogram parameters, according to an extended study in 
models of calcium chloride and adrenal arrhythmia. Intravenous injection of 0.125 mg/kg 
alaglizin prior to exposure to a lethal dose of calcium chloride blocked arrhythmia in 80% 
of rats; 0.250 mg/kg of alaglizin applied after arrhythmogenic СаCl2 stopped the already 
developed arrhythmia in 50% of animals. A single injection of 0.125 mg/kg and 0.250 
mg/kg alaglizin in a model of adrenal arrhythmia prevented full development of 
arrhythmia; 50% and 100 % of animals recovered normal ECG parameters on receiving 
0.125 mg/kg and 0.250 mg/kg alaglizin, respectively. Alaglizin in the model had an ЕD50 of 
0.125 mg/kg body weight against 0.290 mg/kg in LA and thus contained 14 times lower 
lappaconitine.   
The NF:GA complex exerted hypotensive action on intravenous injection of its water 
solution in rats at a dose with ten times lower NF [51, 52]. The hypotensive effect of GA 
complexing with nisoldipine (another dihydropyridine) was similar to that of complexes 
with AG.  
Complexing can have an important consequence of amplifying the pleiotropic effect of 
pharmacons (see above), such as NF. The wanted antiarrhythmic effect of NF can be only 
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achieved with a dose that causes almost critical blood pressure drop, but the NF:GA 
complex induces the same effect with 29 times lower NF than the hypotensive dose.  
Thus, the NF:GA complex is a promising parenteral drug with universal activity against 
hypertensive crises attendant with arrhythmia.  
A presumable action mechanism of the NF:GA complex was studied in vitro on neurons 
isolated from peripharyngeal ganglia of Lymnacea stagnalis molluscs. The provoked 
responses are arrested completely with an NF concentration as high as 3.0 mM but with 30 
times as low concentration (0.1 mM) of NF:GA. The responses to NF are blocked faster and 
recover sooner after neuron washing than the responses induced by the complex, which 
indicates stronger binding of the latter with receptors and its more prolonged action. The 
higher receptor affinity of the complex is corroborated by comparing the NF and NF:GA 
effects on calcium channels [51] (Fig. 8) 
 
1. amplitude of calcium currents induced by Nifedipine. 
2. amplitude of calcium currents induced by Nifedipine clathrate with glycyrrhizic acid. 
Upward arrows show start point of the blocker action. Downward arrows show start point of blockers washout. 
X axis set as time in minutes. 
Y axis set as amplitude of incoming current in pA. 
Figure 8. Averaged changes in calcium current amplitude induced by action and washout of blockers 
within a group of neurons (12 cells in each group). 
The propranolol-GA complex studied in terms of hypotensive activity ensured 14% blood 
pressure drop in normotensive animals at a dose of 0.2 mg/kg body weight (minimum dose 
0.0025 mg/kg gave a 11% decrease). Pure propranolol decreases blood pressure for 11% in a 
dose of 0.2 mg/kg; a similar pressure drop may be achieved by the minimum dose 0.0025 
mg/kg, but it is statistically unconfident. Therefore, complexing enhances and stabilizes the 
hypotensive action of propranolol and allows 12.5-fold reduction of its dose.   
Furthermore, complexing amplifies the antiarrhythmic action (pleiotropic effect) of 
propranolol. Namely, 100% of animals exposed to 0.3 mg/kg arrhythomogenic 0.1 % 
adrenalin survived on administration of 0.0025 mg/kg GA:Propranolol, while only 40 % 
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survived among those who received 0.0002 mg/kg propranolol (this being the dose 
contained in the complex). Control animals responded to adrenalin by fatal disrhythmia 
grading into ventricular fibrillation, and 100% of them died [53]. 
The complex of GA with anticoagulant warfarin was investigated in a dose of 20 mg/kg 
body weight, which corresponds to 2 mg/kg WF. Prothrombin time was first measured six 
hours after a single intragastric injection. The interval was chosen proceeding from 
pharmacokinetics of warfarin: its plasma metabolites reach the maximum in 6-12 hours in 
rats [54]. In our experiments, PT has shown a confident change only in the positive control 
group with 2 mg/kg WF, but it is not clinically significant as it fails to ensure the required 
increase in coagulation time. A significant PT increase was observed on single intragastric 
administration of WF, while the WF:GA complex induced a smooth PT rise as late as in 30 
hours (two injections) after the beginning of the experiment and the values corresponding to 
the positive control (WF) were reached only in 54 hours (three injections). Thus, WF:GA 
complexing made WF more soluble in water but slowed down its wanted anticoagulant 
action, possibly because GA molecules screened its active centers (Fig. 9). 
 
Figure 9. Prothrombin time of WF:GA 
3.2.4. Psychotropic drugs 
The complexation effect was discovered in a pharmacological study of GA complexes with 
antidepressant fluoxetine and with anxiolytic gamma-amino-beta-phenylbutirate 
hydrochloride. Fluoxetine (FL), N-methyl-3-phenyl-3-[4-(trifluoromethyl)phenoxy]propan-
1-amine acts as a depression antagonist by inhibiting serotonin neuronal uptake in CNS. 
Antidepressants are known to have many drawbacks, such as large doses, a narrow activity 
spectrum, high toxicity and prolonged elimination that involves liver cells and exerts 
deleterious effects on the renal function.  
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The study of fluoxetine complexes with GA (hereafter fluaglizin) aimed primarily  
at checking the possibility to alleviate the side effects of the pharmacon. In preliminary 
testing, the 1:10 FL:GA complex showed the highest activity. The complex, with 0.072 
pharmacon parts in its one weight part, was patented under the name of fluaglizin (FG) 
[55,56]. Note that its LD50 exceeds 5000 mg/kg body weight against LD50 =248 mg/kg  
in fluoxetine.  
Fluaglizin exerts a more prominent antidepressant effect than fluoxetine on single-dose 
administration in the Porsolt test and is a stronger serotonin uptake inhibitor. For instance, it 
suppressed the action of chloral hydrate more effectively than fluoxetine in a test with 5-
hydroxytryptophan. Like fluoxetine, fluaglizin lacks anxiolytic activity.  
The antidepressive effect of fluaglizin was identical to that of fluoxetine in a model of social 
depression in mice, namely, the animals became twice more communicative toward familiar 
and unfamiliar partners (had twice greater frequency and time of contacts). The dose of 
fluoxetine in the FL:GA complex is 1.08 mg/kg body weight against the standard 15 mg/kg. 
Fluaglizin, like fluoxetine, prevents blood glucose drop and attenuates peroxidation 
normalizing the antioxidant status of depressed individuals [55, 56].  
In order to understand the mechanism of FL:GA action and compare it with fluoxetine, we 
studied its effect on contents of catecholamines and their precursors in different brain parts 
on single and therapeutic 25 mg/kg administration. The 17 times lower dose of fluoxetine in 
FL:GA complexes induced a weaker effect on serotonin uptake and triggered dophamine 
exchange in brain [57]. The nootropic activity of fluoxetine, first mentioned in [48], shows up 
also in the FL:GA complex.  
Fluoxetine (30 μM) is known to suppress epileptiform activity which is evident in  
50% lower-amplitude oscillations of electric potential (reflecting the activity of nerve  
cells) in response to pulse stimulation of hippocampus on the background of picrotoxin 
action.   
Like fluoxetine, fluaglizin inhibits bikukulin-induced epileptiform activity in hippocampus 
sections in rats and acts as epilepsy antagonist [48]. 
Phenybut (FB), 4-amino-3-phenyl-butyric acid, is a nootropic and tranquilizing drug which 
relieves stress and anxiety and improves sleep. It is used in clinical practice against asthenia, 
neurotic anxiety, and sleep disorders, prior to surgery, and for preventing naupathia. It, 
however, has drawbacks of inducing somnolence and allergic reactions.  
The FB:GA complex is twice less toxic than FB and stimulates cognitive activity in the same 
way as the pharmacon and GABA but, unlike the two latter, it provides a 20% increase in 
memorizing abilities in animals and attenuates sedative effects [48]. 
3.2.5. Anticancer drugs 
GA complexes (1:1) with 5-fluorouracil, tegafur, and daunorubicin hydrochloride were 
synthesized in solution [58]. Complexing decreases the toxicity of the drugs and increases 
 
The Complex World of Polysaccharides 596 
their solubility in water. The GA complex with fluorouracil exerts antineoplastic action with 
respect to Pliss lymphosarcoma, B-16 melanoma, and Geren carcinoma. The effective indices 
are, respectively, 3.05; 2.11, and 1.76. The tumor growth inhibition is 67.2%; 53.4 %; 87.1 %. 
3.3. Antimicrobial drugs  
GA complexes with antibiotiсs (chloramphenicol) and sulfanilamides 
(sulfamethoxypyridazine, saladimetoxine, sulfamonomethoxine, sulfadimidine, and 
sulfaguanidine), as well as with isoniazid and nitrofural, 1:1, were likewise synthesized  
in solution and compared in terms of their microbial activity. The highest survival rate 
(90%) was observed on the 10th day after exposure to infection in animals with 
staphylococcosis that received 50 mg/kg GA-chloramphenicol, while only 30% survived 
when pure chloramphenicol was given. The percentage of survived animals with 
Pseudomonas aeruginosa, Proteus vulgaris, and E. coli infections reached 80% on GA: 
chloramphenicol administration but it was only 20-50% on treatment with free 
chloramphenicol. The complex was also shown to stimulate humoral and cell immune 
responses [59]. 
3.4. Simvastatin (hypocholesterolemic drug) 
Inhibitors of 3-hydroxy-3-methylglutaryl coenzyme A (3HMG-CoA) reductase, the so-called 
statins, are known to successfully reduce low-density lipoproteins, and are used for this in 
atherosclerosis therapy. However, most statins cause side effects and have to be replaced by 
safer drugs, with a more prolonged action. NMR spectroscopy of the behavior of 
simvastatin (SMS) in solutions with GA indicates formation of stable complexes. The 
synthesized SMS:GA complex is stable in water solutions at GA above 0.2 mM [60]. The 
complex patented as simvaglysine (SMG) [61] demonstrates uncompetitive inhibition of 
3HMG-CoA reductase. SMG, in doses with three times lower statin, turns out to be more 
potent and safer than SMS.  
Thus, simvaglysine acts as an uncompetitive inhibitor/proinhibitor of the 3HMG-CoA 
reductase reaction by inducing inhibition of cholesterol synthesis in liver microsomal 
fraction of rats in vitro, being no less potent than simvastatin. Within the inhibition constants 
from 100 to 300 nM, SMS inhibits 37.7- 42.0% mevalonate formation, while SMG provides a 
31-33% total blood cholesterol decrease after 14 days of administration in rats with 
hypercholesterolemia, at doses with 3 times lower SMS, which is as effective as the 
therapeutic dose of simvastatin. The greater safety of SMG is confirmed by a lower blood 
CPK (creatine phosphokinase) increase after 14 days of treatment than in the case of SMS: 
2.3 lower than with 2-5 times larger SMS doses [60, 61]. 
4. Conclusion  
Thus, water-soluble molecular complexes of various polysaccharides and glycyrrhizic  
acid with drugs that normally dissolve poorly in water have been synthesized and tested  
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for binding strength and pharmacological activity in comparison with the constituent  
drugs.  
The suggested mechanochemical synthesis of solid dispersed systems “drug-complexing 
agent” ensures high strength of the complexes, on condition of low-energy nondestructive 
treatment of polysaccharide macromolecules.  
Arabinogalactan, a water soluble polysaccharide of Larix sibirica Ledeb. and Larix gmelinii 
(Rupr.), when used as a complexing agent, provides the highest solubility among other 
studied poly- and oligosaccharides. Another advantage of arabinogalactan is its exceptional, 
almost infinite, raw material source in the Northern Hemisphere (in Russia and Canada), as 
well as the availability of extraction and purification technologies [62]. 
The molecules of poorly water soluble drugs can be carried by micelles that form in  
water solutions of glycyrrhizic acid. Complexing with polysaccharides, in the same  
way as with GA, increases the solubility of pharmacons and allows reducing significantly 
(up to ten times) the effective dose avoiding, at the same time, some unwanted side  
effects.   
Thus, a new perspective is opening of obtaining highly effective and safe drugs and new 
ways of drug delivery.  
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